Meta description: Morphocell Technologies closes a $50 million Series A financing with global investors to expand regenerative medicine programs and establish its first European base.
Morphocell Technologies Inc., a Canadian regenerative medicine startup focused on tissue and organ replacement therapies, has completed its Series A funding round at a total of $50 million. The final close follows a $10 million add-on investment led by Investissement Québec and CDP Venture Capital, bolstering the company’s capital position and operational runway.
Who invested in this round?
The Series A financing began with a $40 million close in February 2024 led by Genson Capital. The latest $10 million extension brought in two new leading institutions. Investissement Québec increased its commitment, and CDP Venture Capital, part of Italy’s Cassa Depositi e Prestiti group, joined the investor syndicate. Both organizations operate with long-term investment mandates and a strategic focus on innovation-driven sectors.
This expansion of the investor base reinforces Morphocell’s financial strength ahead of clinical and manufacturing milestones. The combined support now positions the company among the better-funded private regenerative medicine enterprises in Canada.
What does this mean for growth?
With $50 million now secured, Morphocell has extended its operating runway to over three years. The funding enables the company to accelerate its lead program, ReLiver, toward clinical proof-of-concept. Additional capital will go toward expanding in-house manufacturing capabilities and growing the team of scientific and operational experts.
Since early 2024, Morphocell’s team has expanded to 44 employees across locations in Greater Montréal, Cambridge in Boston, and Toronto. The vertically integrated structure covers discovery, cell production, and preclinical work, setting a comprehensive base for progression to human trials.
Why open a European subsidiary?
Part of the financing will support the creation of Morphocell’s first European subsidiary in Italy. This decision aligns with its founders’ Italian background and taps into the country’s biotechnology talent pool and research infrastructure. Establishing a European base strengthens connections to regional innovation ecosystems and creates opportunities for partnerships to advance regenerative medicine programs.
CDP Venture Capital’s involvement played a key role in shaping the European expansion strategy. The new subsidiary will serve as a platform for research collaboration and a gateway into broader European markets.
FAQ
- How much funding has Morphocell raised in total?
The Series A now totals $50 million after a $10 million extension. - Who are the major investors?
Genson Capital, Investissement Québec, and CDP Venture Capital are the key backers. - What is the primary focus of the new funds?
Advancing the ReLiver program, expanding manufacturing, and growing the team. - Why Italy for the European subsidiary?
It leverages local talent, research institutions, and strategic investor support from CDP Venture Capital.
Key takeaways
Morphocell Technologies’ completion of its Series A round marks a pivotal growth point. The combination of domestic and international institutional investors expands its resources and strategic reach. The funds will accelerate development of liver disease therapies, scale manufacturing, and enhance global collaboration capabilities. For investors and founders, the deal illustrates the value of building cross-border investor networks in life sciences.
Disclaimer
This content is for informational purposes only. It does not constitute investment advice or an offer to invest.